{
    "pmcid": "8863326",
    "qa_pairs": {
        "How does saRBD-1 neutralize SARS-CoV-2 variants?": [
            "By blocking the interaction between the spike protein and ACE2",
            "By degrading the viral RNA genome",
            "By binding to the viral envelope and causing lysis",
            "By preventing the assembly of viral particles"
        ],
        "What characteristic of saRBD-1 allows it to maintain efficacy against multiple SARS-CoV-2 variants?": [
            "It targets a conserved epitope within the RBD",
            "It binds to multiple sites on the spike protein",
            "It induces a strong immune response in host cells",
            "It enhances the production of host antiviral proteins"
        ],
        "What class of neutralizing antibody is saRBD-1 suggested to be, based on competitive binding assays?": [
            "Class 1 neutralizing antibody",
            "Class 2 neutralizing antibody",
            "Class 3 neutralizing antibody",
            "Class 4 neutralizing antibody"
        ],
        "What is the primary target of the alpaca-derived nanobody saRBD-1?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The S2 subunit of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2"
        ],
        "What modification was made to saRBD-1 to enhance its neutralization potency?": [
            "It was engineered into bivalent and Fc-conjugated constructs",
            "It was conjugated with a fluorescent dye",
            "It was combined with a small molecule inhibitor",
            "It was encapsulated in lipid nanoparticles"
        ]
    }
}